180 related articles for article (PubMed ID: 38585151)
1. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis.
Desaintjean C; Ahmad K; Traclet J; Gerfaud-Valentin M; Durel CA; Glerant JC; Hot A; Lestelle F; Mainbourg S; Nasser M; Seve P; Turquier S; Devouassoux G; Cottin V
Front Med (Lausanne); 2024; 11():1341310. PubMed ID: 38585151
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
[TBL] [Abstract][Full Text] [Related]
3. Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis.
Guntur VP; Manka LA; Denson JL; Dunn RM; Dollin YT; Gill M; Kolakowski C; Strand MJ; Wechsler ME
J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1186-1193.e1. PubMed ID: 33065367
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
[TBL] [Abstract][Full Text] [Related]
5. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study.
Bettiol A; Urban ML; Padoan R; Groh M; Lopalco G; Egan A; Cottin V; Fraticelli P; Crimi C; Del Giacco S; Losappio L; Moi L; Cinetto F; Caminati M; Novikov P; Berti A; Cameli P; Cathébras P; Coppola A; Durel CA; Folci M; Lo Gullo A; Lombardi C; Monti S; Parronchi P; Rivera CM; Solans R; Vacca A; Espígol-Frigolé G; Guarnieri G; Bianchi FC; Marchi MR; Tcherakian C; Kahn JE; Iannone F; Venerito V; Desaintjean C; Moroncini G; Nolasco S; Costanzo GAML; Schroeder JW; Ribi C; Tesi M; Gelain E; Mattioli I; Bello F; Jayne D; Prisco D; Vaglio A; Emmi G;
Lancet Rheumatol; 2023 Dec; 5(12):e707-e715. PubMed ID: 38251561
[TBL] [Abstract][Full Text] [Related]
6. Benralizumab for eosinophilic granulomatosis with polyangiitis.
Cottu A; Groh M; Desaintjean C; Marchand-Adam S; Guillevin L; Puechal X; Beaumesnil S; Lazaro E; Samson M; Taille C; Durel CA; Diot E; Nicolas S; Guilleminault L; Ebbo M; Cathebras P; Dupin C; Yildiz H; Belfeki N; Pugnet G; Chauvin P; Jouneau S; Lifermann F; Martellosio JP; Cottin V; Terrier B;
Ann Rheum Dis; 2023 Dec; 82(12):1580-1586. PubMed ID: 37550002
[TBL] [Abstract][Full Text] [Related]
7. Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis.
Koga Y; Aoki-Saito H; Kamide Y; Sato M; Tsurumaki H; Yatomi M; Ishizuka T; Hisada T
Front Pharmacol; 2022; 13():865318. PubMed ID: 35359852
[TBL] [Abstract][Full Text] [Related]
8. Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis.
Martínez-Rivera C; Garcia-Olivé I; Urrutia-Royo B; Basagaña-Torrento M; Rosell A; Abad J
BMC Pulm Med; 2021 Jan; 21(1):35. PubMed ID: 33478439
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
[TBL] [Abstract][Full Text] [Related]
10. Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis.
Vultaggio A; Nencini F; Bormioli S; Vivarelli E; Dies L; Rossi O; Parronchi P; Maggi E; Matucci A
Allergy Asthma Immunol Res; 2020 Sep; 12(5):885-893. PubMed ID: 32638567
[TBL] [Abstract][Full Text] [Related]
11. Real-world characteristics of "super-responders" to mepolizumab and benralizumab in severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis.
Portacci A; Campisi R; Buonamico E; Nolasco S; Pelaia C; Crimi N; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Scichilone N; Pelaia G; Crimi C; Carpagnano GE
ERJ Open Res; 2023 Sep; 9(5):. PubMed ID: 37908397
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL5 therapies for asthma.
Farne HA; Wilson A; Powell C; Bax L; Milan SJ
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD010834. PubMed ID: 28933516
[TBL] [Abstract][Full Text] [Related]
13. Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months.
Kayser MZ; Drick N; Milger K; Fuge J; Kneidinger N; Korn S; Buhl R; Behr J; Welte T; Suhling H
J Asthma Allergy; 2021; 14():863-871. PubMed ID: 34285513
[TBL] [Abstract][Full Text] [Related]
14. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
Yamane T; Hashiramoto A
Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
[TBL] [Abstract][Full Text] [Related]
17. Anti-IL-5 therapies for asthma.
Farne HA; Wilson A; Milan S; Banchoff E; Yang F; Powell CV
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD010834. PubMed ID: 35838542
[TBL] [Abstract][Full Text] [Related]
18. [Anti-IL-5 in severe asthma associated with eosinophilic granulomatosis with polyangiitis. Real-life study].
Akdime F; Habib S; Regard L; Terrier B; Cohen P; Mouthon L; Guillevin L; Burgel PR; Honore I; Puéchal X; Roche N
Rev Mal Respir; 2023; 40(9-10):732-742. PubMed ID: 37923651
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL5 Monoclonal Antibodies Reduce Asthma Exacerbations and Corticosteroids Dose in Three Eosinophilic Granulomatosis with Polyangiitis Case Reports.
Skouvaklidou E; Kipourou M; Zisopoulos D; Vounotrypidis P; Katsoulis K
Mediterr J Rheumatol; 2023 Jun; 34(2):238-244. PubMed ID: 37654647
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
